June 4, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
May 13, 2024
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 10, 2024
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
May 3, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
April 5, 2024
Praxis Precision Medicines to Participate in Upcoming April Conferences
April 2, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
March 27, 2024
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Displaying 1 - 10 of 19